{
    "id": 2925,
    "fullName": "SMYD3 over exp",
    "impact": "none",
    "proteinEffect": "no effect",
    "geneVariantDescriptions": [
        {
            "description": "SMYD3 over exp indicates an over expression of the Smyd3 protein and/or mRNA. However, the mechanism causing the over expression is unspecified.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 64754,
        "geneSymbol": "SMYD3",
        "terms": [
            "SMYD3",
            "bA74P14.1",
            "KMT3E",
            "ZMYND1",
            "ZNFN3A1"
        ]
    },
    "variant": "over exp",
    "createDate": "01/12/2015",
    "updateDate": "08/02/2017",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 11596,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCI-121 selectively inhibited growth of lung cancer cell lines with high Smyd3 expression level in culture (PMID: 25728514).",
            "molecularProfile": {
                "id": 2747,
                "profileName": "SMYD3 over exp"
            },
            "therapy": {
                "id": 6073,
                "therapyName": "BCI-121",
                "synonyms": null
            },
            "indication": {
                "id": 1324,
                "name": "lung cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9659,
                    "pubMedId": 25728514,
                    "title": "A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25728514"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11598,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCI-121 selectively inhibited growth of prostate cancer cell lines with high Smyd3 expression level in culture (PMID: 25728514).",
            "molecularProfile": {
                "id": 2747,
                "profileName": "SMYD3 over exp"
            },
            "therapy": {
                "id": 6073,
                "therapyName": "BCI-121",
                "synonyms": null
            },
            "indication": {
                "id": 10283,
                "name": "prostate cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9659,
                    "pubMedId": 25728514,
                    "title": "A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25728514"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 1606,
            "approvalStatus": "Preclinical",
            "evidenceType": "Emerging",
            "efficacyEvidence": "SMYD3 methylates MAP3K2 influencing Ras/Raf/MEK/ERK signaling in cells and SMYD3 over expression has been documented in a variety of cancers. In a preclinical study, SMYD3 depletion enhanced the anti-tumerogenic effect of the MEK inhibitor Trametinib in cancer cell lines highlighting Smyd3 as a potential therapeutic target (PMID: 24847881).",
            "molecularProfile": {
                "id": 2747,
                "profileName": "SMYD3 over exp"
            },
            "therapy": {
                "id": 1776,
                "therapyName": "N/A",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "not applicable",
            "references": [
                {
                    "id": 1635,
                    "pubMedId": 24847881,
                    "title": "SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/24847881"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 11597,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCI-121 inhibited growth of pancreatic cancer cells with high Smyd3 expression level in culture (PMID: 25728514).",
            "molecularProfile": {
                "id": 2747,
                "profileName": "SMYD3 over exp"
            },
            "therapy": {
                "id": 6073,
                "therapyName": "BCI-121",
                "synonyms": null
            },
            "indication": {
                "id": 1793,
                "name": "pancreatic cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9659,
                    "pubMedId": 25728514,
                    "title": "A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25728514"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11600,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCI-121 selectively inhibited growth of cancer cell lines with high Smyd3 expression level in culture (PMID: 25728514).",
            "molecularProfile": {
                "id": 2747,
                "profileName": "SMYD3 over exp"
            },
            "therapy": {
                "id": 6073,
                "therapyName": "BCI-121",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9659,
                    "pubMedId": 25728514,
                    "title": "A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25728514"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11599,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCI-121 selectively inhibited growth of ovarian cancer cell lines with high Smyd3 expression level in culture (PMID: 25728514).",
            "molecularProfile": {
                "id": 2747,
                "profileName": "SMYD3 over exp"
            },
            "therapy": {
                "id": 6073,
                "therapyName": "BCI-121",
                "synonyms": null
            },
            "indication": {
                "id": 2394,
                "name": "ovarian cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9659,
                    "pubMedId": 25728514,
                    "title": "A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25728514"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 11595,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, BCI-121 selectively inhibited growth of colorectal cancer cell lines with high Smyd3 expression level in culture (PMID: 25728514).",
            "molecularProfile": {
                "id": 2747,
                "profileName": "SMYD3 over exp"
            },
            "therapy": {
                "id": 6073,
                "therapyName": "BCI-121",
                "synonyms": null
            },
            "indication": {
                "id": 9256,
                "name": "colorectal cancer",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 9659,
                    "pubMedId": 25728514,
                    "title": "A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25728514"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2747,
            "profileName": "SMYD3 over exp",
            "profileTreatmentApproaches": [
                {
                    "id": 14053,
                    "name": "BCI-121",
                    "profileName": "SMYD3 over exp"
                }
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}